Professor Sharon Sha of Stanford University is presenting on the progress of POLARIS-AD at ADPD 2026. Provided by Aribio

Professor Sharon Sha of Stanford University is presenting on the progress of POLARIS-AD at ADPD 2026. Provided by Aribio

View original image

Aribio drew attention by releasing the latest progress of its oral Alzheimer's treatment, AR1001, in a global Phase 3 clinical trial at an international conference on Alzheimer's and Parkinson's diseases.


On March 24, Aribio announced that it had presented updates on the global Phase 3 trial (POLARIS-AD) of AR1001 at the International Conference on Alzheimer's and Parkinson's Diseases (ADPD 2026). The conference took place in Copenhagen, Denmark, from March 17 to 21 (local time) and was a major event attended by more than 5,500 experts from over 70 countries.


The presentation was delivered by Sharon Sha, Director of the Stanford University Memory Disorders Center. The AR1001 global Phase 3 trial is being conducted across 230 institutions in 13 countries, targeting 1,535 patients with early-stage Alzheimer's disease. The trial consists of a 52-week main study followed by a 52-week extension study.


The trial completion rate has surpassed 90%. Over 95% of patients who completed the main trial voluntarily enrolled in the extension study, while the dropout rate stood at approximately 15%, below the initial projection of 25%, indicating stable trial operations. The company plans to complete dosing within the second quarter and announce topline results in the third quarter.


Aribio expects that if AR1001 demonstrates meaningful results in the late-stage clinical trial, it could become an oral alternative in a treatment market currently dominated by antibody injections. Currently, Kisunla, one of the major Alzheimer's treatments approved in the United States, is administered via intravenous infusion every four weeks, while Leqembi has been associated with MRI monitoring issues related to amyloid-related imaging abnormalities (ARIA).


Jaejoon Chung, CEO of Aribio, stated, "Through this ADPD presentation ahead of the clinical trial completion in June, we have demonstrated the global competitiveness of the AR1001 Phase 3 trial and the validity of its data-driven design. The possibility of establishing a new global standard as an oral Alzheimer's treatment has increased significantly."


He added, "This ADPD presentation was more than just a conference participation; it was a meaningful event that highlighted key factors for investment assessment—such as the scale of the clinical trial, low dropout rate, high extension participation rate, and the convenience of oral administration—at a crucial time ahead of the topline results announcement in the third quarter."



Meanwhile, Aribio is in the process of merging with Kosdaq-listed Solux, with the merger scheduled for June 5, 2026.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing